PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Aimmune Therapeutics, Inc. ("Aimmune") (NASDAQ: AIMT) on behalf of the company's shareholders.
On August 31, 2020, Aimmune announced that it had entered into an agreement to be acquired by Sociétés des Produits Nestlé, S.A. ("Nestle") for $34.50 per share in an all-cash transaction.
The firm's investigation seeks to determine whether Aimmune's directors breached their fiduciary duties in agreeing to sell the company to Nestle, and whether the proposed transaction as structured undervalues Aimmune's common stock.
Aimmune shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or by email at [email protected] or online at http://kaskelalaw.com/case/aimmune-therapeutics/, for additional information about this investigation and their legal rights and options.
Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
This notice may constitute attorney advertising in certain jurisdictions.
SOURCE Kaskela Law LLC